Drs. Alex Zhavoronkov, Morten Scheibye-Knudsen, Evelyne Bischof and Dominika Wilczok discuss a research paper they co-authored that was published by Aging, entitled, “Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity.”
Aging (Aging-US) Authors
It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.
PRESS RELEASE – On July 28, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new editorial in Volume 16, Issue 14 of Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science), entitled, “Targeted cancer therapy: the initial high concentration may slow down the selection for resistance.”
PRESS RELEASE: On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., published a new brief report in Oncoscience, entitled, “My battle with cancer. Part 1.”
Dr. Mikhail Blagosklonny joins “Master One Thing” host Krister Kauppi to discuss the impact of his rapamycin research and hyperfunciton theory of aging.
PRESS RELEASE: A new research perspective was published in Aging’s Volume 15, Issue 14, entitled, “Towards disease-oriented dosing of rapamycin for longevity: does aging exist or only age-related diseases?”
Dennis Mangan and Dr. Mikhail Blagosklonny discuss how Dr. Blagosklonny’s cancer research led him to the study of aging, whether rapamycin is the most important anti-aging intervention currently available, his skepticism about metformin as an anti-aging drug, and more.